Suppliers and packagers for generic pharmaceutical drug: LEFLUNOMIDE

LEFLUNOMIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905	NDA	sanofi-aventis U.S. LLC	0088-2160-30	1 BOTTLE in 1 CARTON (0088-2160-30) / 30 TABLET, FILM COATED in 1 BOTTLE	1998-09-10
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905	NDA	sanofi-aventis U.S. LLC	0088-2161-30	1 BOTTLE in 1 CARTON (0088-2161-30) / 30 TABLET, FILM COATED in 1 BOTTLE	1998-09-10
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905	NDA	sanofi-aventis U.S. LLC	0088-2162-33	1 BLISTER PACK in 1 CARTON (0088-2162-33) / 3 TABLET, FILM COATED in 1 BLISTER PACK	1998-09-10
Abhai Llc	LEFLUNOMIDE	leflunomide	TABLET;ORAL	212453	ANDA	KVK-Tech, Inc.	10702-277-03	30 TABLET in 1 BOTTLE (10702-277-03)	2020-07-23

Leflunomide Suppliers: Global Manufacturing Landscape and Market Trends

Last updated: February 19, 2026

Leflunomide, an immunosuppressive disease-modifying antirheumatic drug (DMARD), faces a dynamic global manufacturing landscape driven by patent expirations, generic competition, and evolving regulatory requirements. Key suppliers operate across Asia and Europe, with a focus on active pharmaceutical ingredient (API) production and finished dosage form manufacturing. Market trends indicate increasing demand for cost-effective generics and a heightened emphasis on supply chain resilience and quality assurance.

Who are the Major Suppliers of Leflunomide API?

The production of leflunomide API is concentrated among a limited number of specialized chemical manufacturers. These companies often possess expertise in complex organic synthesis and adhere to stringent Good Manufacturing Practices (GMP) required by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Active Pharmaceutical Ingredient (API) Manufacturers:
  • Intas Pharmaceuticals Ltd.: An Indian multinational pharmaceutical company with significant API manufacturing capabilities, including leflunomide. They are a prominent supplier to both regulated and emerging markets.
  • Sun Pharmaceutical Industries Ltd.: Another leading Indian pharmaceutical firm, Sun Pharma is a major global player in generics and actively manufactures leflunomide API.
  • Lupin Ltd.: Headquartered in India, Lupin is a global pharmaceutical company with a strong generics portfolio and robust API manufacturing operations, including leflunomide.
  • Alkem Laboratories Ltd.: An Indian pharmaceutical company that manufactures and markets a range of pharmaceutical products, including APIs for various therapeutic areas, leflunomide among them.
  • Hetero Drugs Ltd.: Based in India, Hetero is one of the largest API manufacturers globally and a significant producer of leflunomide.
  • Mylan N.V. (now part of Viatris): While Mylan has undergone significant corporate restructuring, its historical API manufacturing footprint included leflunomide. Viatris continues to operate in this space.
  • Teva Pharmaceutical Industries Ltd.: A global leader in generics, Teva has a broad API manufacturing network and has been a supplier of leflunomide API.
  • Zydus Lifesciences Ltd. (formerly Cadila Healthcare): An Indian pharmaceutical company with integrated API and finished dosage form capabilities, Zydus is a known producer of leflunomide.
  • IOL Chemicals and Pharmaceuticals Ltd.: This Indian company specializes in bulk drugs and has leflunomide listed in its product portfolio.
  • Novartis AG (through Sandoz): While Novartis was the originator of leflunomide (brand name Arava), its generics division, Sandoz, also participates in API manufacturing or sourcing for its generic formulations.

These API suppliers are critical for the downstream production of generic leflunomide tablets. Their production capacity, quality control standards, and pricing significantly influence the availability and cost of the final drug product.

What are the Key Manufacturers of Finished Leflunomide Dosage Forms?

Finished dosage form manufacturers source API from these suppliers and formulate it into tablets, typically 10 mg, 20 mg, and 25 mg strengths. The market for finished leflunomide products is largely dominated by generic manufacturers.

• Global Generic Manufacturers:
  • Teva Pharmaceutical Industries Ltd.: A major player in the generic leflunomide tablet market in North America and Europe.
  • Mylan N.V. (now Viatris): Offers generic leflunomide tablets, contributing to market accessibility.
  • Sun Pharmaceutical Industries Ltd.: Markets generic leflunomide under various brand names and as a store-brand product.
  • Aurobindo Pharma Ltd.: An Indian company with a significant global presence in generic drug manufacturing, including leflunomide tablets.
  • Dr. Reddy's Laboratories Ltd.: Another prominent Indian generic pharmaceutical company with leflunomide formulations in its portfolio.
  • Torrent Pharmaceuticals Ltd.: Manufactures and markets generic leflunomide in key global markets.
  • Hikma Pharmaceuticals PLC: A multinational pharmaceutical company that supplies generic leflunomide to the U.S. market.
  • Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals): Provides generic leflunomide tablets in multiple regions.
  • Bausch Health Companies Inc.: Offers generic leflunomide in the United States.
  • Sandoz (Novartis): While the originator, Sandoz also competes in the generic leflunomide space.

The competitive landscape for finished dosage forms is characterized by intense price competition, with manufacturers striving for market share through cost efficiencies and broad distribution networks.

What are the Regulatory Considerations for Leflunomide Production?

Leflunomide production, like all pharmaceuticals, is subject to rigorous regulatory oversight. Compliance with international standards is paramount for market access.

• Key Regulatory Bodies:

  • U.S. Food and Drug Administration (FDA): Sets standards for API and finished product manufacturing in the United States. Inspections of manufacturing facilities are routine.
  • European Medicines Agency (EMA): Oversees drug approval and manufacturing standards within the European Union.
  • Pharmaceuticals and Medical Devices Agency (PMDA) in Japan: Regulates drug manufacturing in Japan.
  • Central Drugs Standard Control Organisation (CDSCO) in India: The national regulatory body responsible for drug approval and manufacturing standards in India.

• Compliance Requirements:

  • Good Manufacturing Practices (GMP): Adherence to GMP guidelines is mandatory for all API and finished product manufacturers. This includes strict controls over facilities, equipment, personnel, documentation, and quality control processes.
  • Drug Master Files (DMFs): API manufacturers submit DMFs to regulatory authorities, providing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products.
  • Abbreviated New Drug Applications (ANDAs): Generic finished dosage form manufacturers file ANDAs with the FDA to demonstrate bioequivalence to the reference listed drug and meet all manufacturing and quality standards.
  • Inspections and Audits: Manufacturing sites are subject to periodic inspections by regulatory agencies and internal quality assurance audits to ensure ongoing compliance.
  • Impurity Profiling and Control: Manufacturers must identify, quantify, and control impurities in both API and finished products to ensure safety and efficacy.
  • Stability Testing: Rigorous stability studies are required to determine the shelf life of the drug product under various storage conditions.

Regulatory compliance ensures the quality, safety, and efficacy of leflunomide products. Non-compliance can lead to warning letters, import alerts, product recalls, and ultimately, market withdrawal.

What are the Current Market Trends and Demand Drivers for Leflunomide?

The leflunomide market is primarily driven by the demand for generic alternatives to the originator product.

• Patent Expirations: The patent for the originator leflunomide product has long expired, paving the way for widespread generic entry. This has led to a significant reduction in drug prices.
• Prevalence of Rheumatoid Arthritis and Psoriatic Arthritis: Leflunomide is indicated for the treatment of active rheumatoid arthritis and psoriatic arthritis. The global prevalence of these autoimmune conditions directly influences the demand for leflunomide.
  • Rheumatoid arthritis affects an estimated 0.5% to 1% of the global adult population [1].
  • Psoriatic arthritis affects between 6% and 38% of individuals with psoriasis [2].
• Cost-Effectiveness: In many healthcare systems, particularly those with budget constraints, the lower cost of generic leflunomide makes it a preferred treatment option.
• Physician Prescribing Habits: Prescribing patterns by rheumatologists and dermatologists remain a key factor in leflunomide utilization.
• Emerging Markets: As healthcare access and generic drug availability improve in emerging economies, demand for leflunomide is expected to grow in these regions.
• Supply Chain Dynamics: Recent global events have highlighted the importance of resilient supply chains. Pharmaceutical companies are increasingly focused on diversifying their supplier base and ensuring reliable sourcing of APIs and finished products.
• Competition from Biologics: While leflunomide remains a valuable oral DMARD, its use is sometimes influenced by the availability and efficacy of newer biologic DMARDs, particularly in severe or refractory cases of rheumatoid arthritis. However, the cost difference often keeps leflunomide a relevant first-line or second-line option.

What are the Challenges and Opportunities in the Leflunomide Market?

The leflunomide market presents both challenges and opportunities for manufacturers, suppliers, and investors.

• Challenges:

  • Price Erosion: Intense competition among generic manufacturers leads to significant price erosion, impacting profit margins.
  • Regulatory Scrutiny: Evolving regulatory expectations regarding impurity control and supply chain transparency require continuous investment in quality systems.
  • Supply Chain Disruptions: Geopolitical events, natural disasters, and global health crises can disrupt the supply of raw materials and finished products, necessitating robust risk management strategies.
  • Therapeutic Alternatives: The development of new and more targeted therapies, including biologics, poses a competitive threat.
  • Counterfeit Products: The threat of counterfeit leflunomide products entering the market requires vigilant monitoring and strong brand protection measures.

• Opportunities:

  • Emerging Market Penetration: Expanding market access and distribution networks in developing countries offers significant growth potential.
  • Vertical Integration: Companies with integrated API and finished dosage form manufacturing capabilities can achieve better cost control and supply chain security.
  • Contract Manufacturing: Opportunities exist for contract manufacturing organizations (CMOs) that can offer specialized synthesis or formulation services for leflunomide.
  • Quality and Reliability: Suppliers demonstrating superior quality control, regulatory compliance, and supply chain reliability can command a premium and secure long-term contracts.
  • Process Optimization: Continuous improvement in manufacturing processes to enhance yields, reduce waste, and lower production costs remains an ongoing opportunity for API manufacturers.
  • Combination Therapies: While not a primary current market driver, exploring potential synergies with other therapeutic agents could present future opportunities.

The leflunomide market, while mature, continues to evolve. Suppliers and manufacturers must remain agile, focused on quality and cost-efficiency, and responsive to global regulatory and market dynamics to maintain a competitive edge.

Key Takeaways

• The leflunomide API market is dominated by manufacturers in India and, to a lesser extent, other global regions.
• Finished dosage form production is largely driven by generic pharmaceutical companies operating globally.
• Regulatory compliance with GMP, DMF filings, and ANDAs is critical for market access.
• Demand is primarily fueled by the prevalence of autoimmune diseases and the cost-effectiveness of generic leflunomide.
• Key market challenges include price erosion and supply chain vulnerabilities, while opportunities lie in emerging markets and specialized manufacturing.

Frequently Asked Questions

1. What is the primary indication for leflunomide? Leflunomide is primarily indicated for the treatment of active rheumatoid arthritis and active psoriatic arthritis [3].

2. How does leflunomide work? Leflunomide is an immunosuppressive disease-modifying antirheumatic drug (DMARD) that inhibits pyrimidine synthesis, thereby reducing lymphocyte proliferation and inflammatory cytokine production [4].

3. Are there any specific purity requirements for leflunomide API? Yes, leflunomide API must meet stringent purity standards as defined by pharmacopeias such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP), which specify acceptable limits for impurities and related substances [5].

4. What is the typical shelf life for leflunomide tablets? The typical shelf life for leflunomide tablets is generally between 24 to 36 months, depending on the specific formulation and storage conditions, as determined by stability testing conducted by the manufacturer [6].

5. Can leflunomide be used in combination therapy? Leflunomide is often used in combination therapy with methotrexate or other DMARDs for rheumatoid arthritis, although specific combination regimens and their efficacy are subject to ongoing clinical evaluation and physician discretion [7].

---

Citations

[1] World Health Organization. (2020). Rheumatoid Arthritis. https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis [2] National Psoriasis Foundation. (n.d.). Psoriatic Arthritis. https://www.psoriasis.org/psoriatic-arthritis/ [3] Leflunomide (Arava®). (n.d.). Rheumatology Network. https://www.rheumatologynetwork.com/view/leflunomide-arav [4] Smolen, J. S., & Aletaha, D. (2012). Rheumatoid Arthritis Therapy: Today and Tomorrow. In K. G. S. S. R. L. D. F. J. M. L. A. T. S. R. L. A. S. S. J. S. T. (Ed.), The American College of Rheumatology Handbook of Clinical Rheumatology. American College of Rheumatology. [5] United States Pharmacopeia. (2023). Leflunomide Monograph. USP-NF 2023. [6] Package Insert for Leflunomide Tablets. (Various Manufacturers). (Refer to specific product labeling for exact shelf-life information). [7] Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Felson, D. T., Sarzi-Puttini, P., et al. (2014). EULAR recommendations for the management of rheumatoid arthritis with neuropsyschiatric comorbidities. Annals of the Rheumatic Diseases, 73(3), 473–481.